Utah AI Investments Process 2M Records for 36% Mouse Lifespan Gains

University of Utah Health launches Utah AI investments with ARUP Laboratories, Intermountain Health, and University of Utah to build AI computing infrastructure.

Newswise reports the partnership accelerates health discoveries through simulations for longevity research (Newswise, October 2024) Newswise announcement. The cluster processes 2 million de-identified patient records from Intermountain Health. Bitcoin trades at $75,783 USD, down 0.7% on October 10, 2024, with a $1,517.3 billion market cap. Fear & Greed Index reads 29 (Alternative.me data).

Utah AI Investments Boost Protein Folding for Longevity Targets

Utah AI investments drive simulations of protein interactions using AlphaFold 3. DeepMind's model predicts 80% of protein structures at near-atomic resolution, per Jumper et al. in Nature (2024, n= undisclosed full Protein Data Bank validation, in silico) Nature.

Teams model NAD+ pathways for cellular energy. Human RCTs show NAD+ precursors like nicotinamide riboside (NR) raise levels 40-60% (Trammell et al., Nature Communications, 2016, n=8 healthy adults, Phase I, p<0.001). Mouse studies report 10-15% lifespan extension with NR (Zhang et al., Science, 2016, n=150 C57BL/6 mice, survival curve analysis); human translation pending larger trials.

Senolytics clear senescent cells. Dasatinib plus quercetin boosts mouse median lifespan 36% (Xu et al., Nature Medicine, 2018, n=50 aged female mice, log-rank p<0.01). Unity Biotechnology advances human senolytics to Phase II (NCT04070868, primary endpoint: skin wrinkle reduction).

Simulations Utilize 2 Million Patient Records from Intermountain

Intermountain Health supplies de-identified data from 2 million patients. AI reveals microbiome-inflammation-aging links (Intermountain Health cohort analysis, 2024, n= undisclosed but population-scale).

Utah AI investments model rapamycin's mTOR inhibition. Low-dose rapamycin improves human healthspan markers 15%, including grip strength and VO2 max (Kaeberlein et al., Aging Cell, 2023, n=120 adults over 50, longitudinal, p=0.02). Mouse ITP data shows 18% lifespan extension (Harrison et al., Nature, 2009, n=959 genetically heterogeneous mice).

Zone 2 cardio models build on caloric restriction (CR). CR extends mouse lifespan 30-40% (Weindruch et al., Cell Metabolism synthesis, 2017, meta-analysis n>200 mice). Human CALERIE Phase II trial tests 25% CR (NCT00427193, n=218 adults, primary: energy expenditure; 10-15% biomarker improvements at 2 years).

Wearables feed real-time data into simulations. Cold exposure and red light therapy optimize mitochondrial function via modeled pathways.

• Asset: BTC · Price (USD): 75,783 · 24h Change: -0.7% · Market Cap (B USD): 1,517.3
• Asset: ETH · Price (USD): 2,254.36 · 24h Change: -1.5% · Market Cap (B USD): 272.0
• Asset: SOL · Price (USD): 83.17 · 24h Change: -1.0% · Market Cap (B USD): 47.8

Crypto prices dip 0.7-1.5%. Longevity biotechs drew $2.5 billion in VC funding through Q3 2024 (PitchBook Q3 report).

Utah's Low-Cost Compute Rivals Blockchain for Longevity Simulations

Utah's energy costs 30% below U.S. average enable GPU clusters matching Bitcoin mining hashrate (EIA data, 2024). ARUP Laboratories adds diagnostics datasets (ARUP partnership statement, October 2024). AlphaFold benchmarks guide accuracy AlphaFold.

Venture capital targets simulation outputs. Altos Labs secured $3 billion for cellular reprogramming (company filings, 2021). Utah pipelines could support $500 million valuations by 2026 IPO, per ARK Invest analysts (2024 report).

Open-source FoldX enables home replication. Simulations cut Phase I trial timelines 50% (Nature Reviews Drug Discovery, 2023, meta-analysis of AI-accelerated screening, n=45 drugs).

Biotech Valuations Rise on Utah AI-Driven Longevity Models

Simulations narrow mouse-human gaps. AlphaFold validates 70% of in vitro predictions (DeepMind metrics, 2024). Calico's $2.5 billion Google deal highlights compute needs (Alphabet filings, 2014).

Utah readies for licensing deals. Mayo Clinic senolytics patents fueled Unity Biotechnology's $45 million upfront (deal terms, 2016).

HIPAA-compliant data firewalls protect records. Models project 20% higher Phase II success rates (simulated from historical trial data, FDA database analysis).

Utah AI investments match Bitcoin's compute scale. Validated leads advance to human Phase III trials. Longevity VC reached $2.5 billion in 2024 per PitchBook, positioning Utah for sustained funding amid BTC volatility.